Glaukos price target raised to $157 from $149 at BTIG

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names reflecting management commentary, product launch momentum, competitive updates, and macroeconomic factors. For Glaukos, with the iDose launch moving into 2025 in a more “coordinated and established manner”, the firm is incorporating its iDose sales estimates into specific revenue estimates going forward, the analyst tells investors in a research note.